In advance of tomorrow's pediatric advisory committee meeting at the FDA, agency staffers are recommending new cautionary language for Eli Lilly's antipsychotic Zyprexa [1] (about the risks of weight gain and diabetes in children) and Novartis' antifungal Lamisil (about the risk of psychiatric side effects, also in children). Report [2]
Links:
[1] http://www.fiercepharma.com/tags/zyprexa
[2] http://www.pharmalot.com/2008/11/fda-staff-suggests-pediatric-warnings-for-zyprexa/